

Financial news for RARE dated on 2020-06-01: Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates

Financial news for RARE dated on 2020-05-21: Ultragenyx Announces Exercise of Option to Purchase Additional Stock of Arcturus Therapeutics

Financial news for RARE dated on 2020-05-19: The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces \$1.34B Common Stock Offering

Financial news for RARE dated on 2020-05-18: Stocks That Hit 52-Week Highs On Monday

Financial news for RARE dated on 2020-05-18: Stifel Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to \$82

Financial news for RARE dated on 2020-05-15: Ultragenyx Announces Data From Confirmatory Cohort Of Phase 1/2 Study Of DTX401 Gene Therapy For Glycogen Storage Disease Type Ia; Says 'All Patients in Cohort 3 Demonstrate Increased Time to Hypoglycemia and a Substantial Reduction in Cornstarch Use'

Financial news for RARE dated on 2020-05-13: Ultragenyx Reports Longer-Term Results From First 3 Cohorts Of Phase 1/2 Study Of DTX301 In Ornithine Transcarbamylase Deficiency: All 3 Patients In Cohort 3 Confirmed Responders

Financial news for RARE dated on 2020-05-13: The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter

Financial news for RARE dated on 2020-05-10: The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight

Financial news for RARE dated on 2020-05-08: Citigroup Maintains Neutral on Ultragenyx Pharmaceutical, Raises Price Target to \$66

Financial news for RARE dated on 2020-05-06: Ultragenyx Pharmaceuticals Sees FY20 Sales Guidance Of \$125M-\$140M

Financial news for RARE dated on 2020-05-06: Ultragenyx Pharmaceutical Q1 EPS \$(2.050) Misses \$(1.690) Estimate, Sales \$36.300M Miss \$36.580M Estimate

Financial news for RARE dated on 2020-05-06: The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle

Financial news for RARE dated on 2020-05-04: GeneTx And Ultragenyx Announce GTX-102 Granted Fast Track Designation By US FDA For Treatment Of Angelman Syndrome

Financial news for RARE dated on 2020-04-28: The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update

Financial news for RARE dated on 2020-04-01: Ultragenyx Earlier Enters into Strategic Partnership with Daiichi Sankyo for Gene Therapy Manufacturing Technology; Ultragenyx To Receive \$200M Upfront, Including \$125M In Cash And \$75M Via Equity Investment

Financial news for RARE dated on 2020-04-01: The Daily Biotech Pulse: InflaRx Begins Human Testing For COVID-induced Pneumonia, Chembio, Becton Dickinson Launch Coronavirus Tests

Financial news for RARE dated on 2020-03-31: REGENXBIO, Ultragenyx Report New License Deal For Use Of NAV Technology Platform For Treatment Of Rare Metabolic Disorder; REGENXBIO To Receive \$7M Upfront Payment

Financial news for RARE dated on 2020-03-18: The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates

Financial news for RARE dated on 2020-03-17: The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment

Financial news for RARE dated on 2020-03-16: Ultragenyx, GeneTx Bio Report First Patient Dosed In KIK-AS Study Of GTX-102 For Angelman Syndrome

Financial news for RARE dated on 2020-03-04: The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies

Financial news for RARE dated on 2020-03-03: Ultragenyx Announces Planned Transition Of Chief Financial Officer

Financial news for RARE dated on 2020-02-27: Ultragenyx And Kyowa Kirin Announce FDA Acceptance And Priority Review Designation Of Supplemental Biologics License

Application For Crysvita For Tumor-Induced Osteomalacia

Financial news for RARE dated on 2020-02-14: Wedbush Maintains Outperform on Ultragenyx Pharmaceutical, Raises Price Target to \$75

Financial news for RARE dated on 2020-02-13: Ultragenyx Pharmaceutical Q4 EPS \$(1.62) Beats \$(1.65) Estimate, Sales \$35.593M Beat \$32.15M Estimate

Financial news for RARE dated on 2020-02-13: The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO

Financial news for RARE dated on 2020-02-09: The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight

Financial news for RARE dated on 2020-01-17: Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to \$77

Financial news for RARE dated on 2020-01-16: The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics

Financial news for RARE dated on 2020-01-15: GeneTx And Ultragenyx Announce Investigational New Drug Application Is Now Active Active For GTX-102 In Patients With Angelman Syndrome; Enrollment In First Phase 1/2 Study Expected To Begin In 1H 2020

Financial news for RARE dated on 2020-01-13: Ultragenyx and Kyowa Kirin Submit Supplemental Biologics License Application to FDA for Crysvita for Tumor-Induced Osteomalacia

Financial news for RARE dated on 2020-01-13: Ultragenyx Sees Prelim. FY19 Sales \$102M-\$104M vs 100.68M Est., Sees Prelim. FY19 Crysvita Sales \$86M-\$88M; Sees FY20 Crysvita Sales In Ultragenyx Territories \$125M-\$140M Excluding EU Royalty Revenue

Financial news for RARE dated on 2020-01-13: 55 Biggest Movers From Friday

Financial news for RARE dated on 2020-01-10: Mid-Afternoon Market Update: Dow Falls 90 Points; RumbleON Shares Plummet

Financial news for RARE dated on 2020-01-10: 40 Stocks Moving In Friday's Mid-Day Session

Financial news for RARE dated on 2020-01-10: Mid-Day Market Update: Crude Oil Down Over 1%; Ultragenyx Pharmaceutical Shares Jump

Financial news for RARE dated on 2020-01-10: Ultragenyx Pharmaceuticals shares are trading higher after the company announced positive topline cohort 3 results and improved longer-term Cohort 2 results from the Phase 1/2 study of DTX301 gene therapy.

Financial news for RARE dated on 2020-01-10: SunTrust Robinson Humphrey Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to \$80

Financial news for RARE dated on 2020-01-10: 33 Stocks Moving in Friday's Pre-Market Session

Financial news for RARE dated on 2020-01-10: The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx

Financial news for RARE dated on 2020-01-09: Ultragenyx Pharmaceuticals shares are trading higher after the company announced positive topline cohort 3 results and improved longer-term Cohort 2 results from the Phase 1/2 study of DTX301 gene therapy.

Financial news for RARE dated on 2020-01-09: Ultragenyx Announces Improved Longer-Term Cohort 2 Results From Phase 1/2 Study Of DTX301 Gene Therapy

Financial news for RARE dated on 2020-01-09: Ultragenyx Announces Topline Cohort 3 Results And Improved Longer-Term Cohort 2 Results From Phase 1/2 Study of DTX301 Gene Therapy In Ornithine Transcarbamylase (OTC) Deficiency

Financial news for RARE dated on 2020-01-02: Benzinga's Top Upgrades, Downgrades For January 2, 2020

Financial news for RARE dated on 2019-12-29: Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus

Financial news for RARE dated on 2019-12-18: Ultragenyx Pharmaceutical Inc Shares To Resume Trade At 9:00 a.m. EDT

Financial news for RARE dated on 2019-12-18: Ultragenyx Sells Future European Royalties On Crysvita For \$320M To Royalty Pharma

Financial news for RARE dated on 2019-12-18: Ultragenyx Shares Halted, News Pending

Financial news for RARE dated on 2019-12-17: 8 Biotech Stocks Morgan Stanley Recommends For 2020

Financial news for RARE dated on 2019-12-17: Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to \$73

Financial news for RARE dated on 2019-12-03: The Gene Therapy Names Moving On The Audentes Buyout Deal

Financial news for RARE dated on 2019-11-19: The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout

Financial news for RARE dated on 2019-11-18: Stocks That Hit 52-Week Lows On Monday

Financial news for RARE dated on 2019-11-13: Stocks That Hit 52-Week Lows On Wednesday

Financial news for RARE dated on 2019-11-08: Stocks That Hit 52-Week Lows On Friday

Financial news for RARE dated on 2019-11-07: Citigroup Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to \$45

Financial news for RARE dated on 2019-11-07: The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs

Financial news for RARE dated on 2019-11-06: Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to \$76

Financial news for RARE dated on 2019-11-06: JMP Securities Maintains Market Outperform on Ultragenyx Pharmaceutical, Lowers Price Target to \$80

Financial news for RARE dated on 2019-11-05: Ultragenyx Pharmaceutical Q3 EPS \$(1.96) Misses \$(1.68) Estimate, Sales \$25.8M Miss \$28.94M Estimate

Financial news for RARE dated on 2019-11-05: The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment

Financial news for RARE dated on 2019-10-14: Ultragenyx Announces FDA Accepts New Drug Application for UX007 for Treatment of Long-chain Fatty Acid Oxidation Disorders

Financial news for RARE dated on 2019-09-30: Ultragenyx and Kyowa Kirin Announce FDA Approves Label Update for Crysvita for the Treatment of X-Linked Hypophosphatemia

Financial news for RARE dated on 2019-09-10: Ultragenyx And Kyowa Kirin Announce Intent To Submit Supplemental Biologics License Application FDA For Crysvita In Tumor-Induced Osteomalacia

Financial news for RARE dated on 2019-09-05: 60 Biggest Movers From Yesterday

Financial news for RARE dated on 2019-09-04: 46 Stocks Moving In Wednesday's Mid-Day Session

Financial news for RARE dated on 2019-09-04: Hearing Ultragenyx Price Target Raised To New Street-High Of \$85 By Leerink Analyst

Financial news for RARE dated on 2019-09-04: 26 Stocks Moving in Wednesday's Pre-Market Session

Financial news for RARE dated on 2019-09-04: Ultragenyx Announces Positive Data from Phase 1/2 Study of DTX401 Gene Therapy in Glycogen Storage Disease Type Ia

Financial news for RARE dated on 2019-08-14: Ultragenyx Announces Partnership With GeneTx To Advance Treatment For Angelman Syndrome; Ultragenyx To Make Upfront Payment Of \$20M For An Exclusive Option To Acquire GeneTx

Financial news for RARE dated on 2019-08-03: The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts

Financial news for RARE dated on 2019-08-02: Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to \$79

Financial news for RARE dated on 2019-08-02: Wedbush Assumes Ultragenyx Pharmaceutical at Outperform, Announces \$75 Price Target

Financial news for RARE dated on 2019-08-01: Ultragenyx Announces Submission Of New Drug Application To FDA For UX007 For Treatment Of Long-Chain Fatty Acid Oxidation Disorders

Financial news for RARE dated on 2019-07-27: The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

Financial news for RARE dated on 2019-07-11: Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.

Financial news for RARE dated on 2019-07-08: Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.

Financial news for RARE dated on 2019-06-19: UPDATE: Arcturus To Receive \$30M In Upfront Payments, Including \$6M In Cash And \$24M Equity Investment At \$10/Share

Financial news for RARE dated on 2019-06-19: Ultragenyx, Arcturus Therapeutics Report Expansion Of Existing Research Collaboration, License Deal To Develop Additional Nucleic Acid Therapies for Rare Diseases

Financial news for RARE dated on 2019-06-17: Shares of several companies in the biotech space are trading higher after Pfizer announced it will acquire Array BioPharma.

Financial news for RARE dated on 2019-06-07: Many US-traded stocks are trading higher as recent economic signals have raised the potential for a Federal Reserve rate cut.

Financial news for RARE dated on 2019-05-06: Ultragenyx Pharmaceutical Q1 EPS \$(1.82) Misses \$(1.74) Estimate, Sales \$18.17M Miss \$18.3M Estimate

Financial news for RARE dated on 2019-05-04: The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs

Financial news for RARE dated on 2019-04-23: Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'

Financial news for RARE dated on 2019-04-18: Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.

Financial news for RARE dated on 2019-04-17: Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.

Financial news for RARE dated on 2019-04-16: Ultragenyx Announces UX007 Granted Fast Track Designation And Rare Pediatric Disease Designation By FDA FDA For Treatment Of Long-Chain Fatty Acid Oxidation Disorders

Financial news for RARE dated on 2019-03-27: Morgan Stanley Upgrades Ultragenyx Pharmaceutical to Overweight, Raises Price Target to \$83

Financial news for RARE dated on 2019-03-26: Ultragenyx Reports Approval Of Crysvida In Brazil For Treatment Of X-Linked Hypophosphatemia In Adults, Children

Financial news for RARE dated on 2019-03-25: These Are Some Of The Best-Performing Leveraged ETFs Of The Year

Financial news for RARE dated on 2019-02-27: Ultragenyx Prices 5.07M Share Public Offering of Common Stock @\$60/Share

Financial news for RARE dated on 2019-02-26: The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote

Financial news for RARE dated on 2019-02-25: Ultragenyx Pharma Reports Offering OF \$250M Common Stock Offering

Financial news for RARE dated on 2019-02-25: Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal

Financial news for RARE dated on 2019-02-21: Ultragenyx Announces 24-week Data From

First Cohort Of Phase 1/2 Study Of DTX401 Gene Therapy In Glycogen Storage Disease Type Ia; Response In Time To Hypoglycemia And Improved Glucose Control Maintained Or Improved In All Three Patients

Financial news for RARE dated on 2019-02-21: Citigroup Maintains Neutral on Ultragenyx Pharmaceutical, Raises Price Target to \$62

Financial news for RARE dated on 2019-02-21: 75 Biggest Movers From Yesterday

Financial news for RARE dated on 2019-02-20: 54 Stocks Moving In Wednesday's Mid-Day Session

Financial news for RARE dated on 2019-02-20: The Daily Biotech Pulse: Teva Settles With FTC, Setback For Merck In Liver Cancer Trial, Sienna Biopharma Offering

Financial news for RARE dated on 2019-02-19: Ultragenyx Pharmaceutical Q4 EPS \$(1.73) Beats \$(1.79) Estimate, Sales \$16.26M Beat \$14.01M Estimate

Financial news for RARE dated on 2019-02-15: The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings

Financial news for RARE dated on 2019-02-14: Ultragenyx, Kyowa Kirin Reports 64-Week Results For Crysvita From Phase 3 Study For X-Linked Hypophosphatemia: 'Results Confirm and Extend 40-Week Findings that Treatment with Crysvita is Superior to Conventional Therapy'

Financial news for RARE dated on 2019-01-04: Ultragenyx Reports Results From 1st Cohort Of Phase 1/2 Study Of DTX401 Gene Therapy In Glycogen Storage Disease Type Ia; Response Observed In All Three Patients And Two Patients Demonstrated Clinically Meaningful Improvement In Time To Hypoglycemia

Financial news for RARE dated on 2019-01-02: 45 Stocks Moving In Wednesday's Mid-Day Session

Financial news for RARE dated on 2019-01-02: Ultragenyx Pharmaceutical shares are trading lower after Raymond James downgraded the stock from Market Outperform to Market Perform.

Financial news for RARE dated on 2019-01-02: Raymond James Downgrades Ultragenyx Pharmaceutical to Market Perform

Financial news for RARE dated on 2018-12-30: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

Financial news for RARE dated on 2018-12-23: The Week Ahead In Biotech: Focus Shifts To Year-End Clinical Trial Results

Financial news for RARE dated on 2018-12-06: Ultragenyx And Kyowa Kirin Announce Health Canada Approval Of Crysvita For The Treatment Of X-linked Hypophosphatemia In Adults And Children

Financial news for RARE dated on 2018-11-14: Ultragenyx Reports Intent To Submit New Drug Application For UX007 For Treatment Of Long-Chain Fatty Acid Oxidation Disorders In Mid 2019

Financial news for RARE dated on 2018-11-08: 8 Biggest Price Target Changes For Thursday

Financial news for RARE dated on 2018-11-08: Benzinga's Top Upgrades, Downgrades For November 8, 2018

Financial news for RARE dated on 2018-11-08: Citigroup Upgrades Ultragenyx Pharmaceutical to Neutral, Raises Price Target to \$54

Financial news for RARE dated on 2018-11-05: Ultragenyx Q3 EPS \$(1.74) Beats \$(1.96) Estimate, Sales \$11.76M Beat \$11.1M Estimate

Financial news for RARE dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for RARE dated on 2018-10-29: Credit Suisse Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to \$59

Financial news for RARE dated on 2018-10-29: SunTrust Robinson Humphrey Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to \$54

Financial news for RARE dated on 2018-10-29: Wedbush Maintains Outperform on Ultragenyx Pharmaceutical, Lowers Price Target to \$88

Financial news for RARE dated on 2018-10-29: 71 Biggest Movers From Friday

Financial news for RARE dated on 2018-10-26: 56 Stocks Moving In Friday's Mid-Day Session

Financial news for RARE dated on 2018-10-26: Ultragenyx Pharma shares are trading lower after the company said it will discontinue development of its UX007 drug candidate.

Financial news for RARE dated on 2018-10-26: Ultragenyx Pharma Shares Down 14% Following Resumption

Financial news for RARE dated on 2018-10-26: Ultragenyx Shares To Resume Trade At 8:30 a.m. EDT

Financial news for RARE dated on 2018-10-26: Ultragenyx Says Co. On Track With Separate UX007 Program In LC-FAOD With Pre-New Drug Application Meeting Later In 2018

Financial news for RARE dated on 2018-10-26: Ultragenyx Reports Will Discontinue Development Of UX007 In Glut1 DS Indication

Financial news for RARE dated on 2018-10-26: Ultragenyx Reports Topline Results From Phase 3 Study Of UX007 In Patients With Glut1 DS With Disabling Movement Disorders: Did Not Achieve Primary Endpoint

Financial news for RARE dated on 2018-10-22: REGENXBIO Reports Exclusive Global License With Ultragenyx For Treatment Of CDKL5 Deficiency Disorder Using NAV Vectors

Financial news for RARE dated on 2018-10-18: Ultragenyx Reports Approval Of Mepsevii In Brazil For Treatment Of Mucopolysaccharidosis VII

Financial news for RARE dated on 2018-09-27: UPDATE: Ultragenyx Says Higher-Dose Cohort 3 Patient Enrollment To Begin In 2018, Sees Data Released Mid 2019

Financial news for RARE dated on 2018-09-27: Ultragenyx Reports Topline Cohort 2 Results From Phase 1/2 Study Of DTX301 In Ornithine Transcarbamylase Deficiency: Normalized 1 Patient In Cohort, Responder Showed 'continued biochemical improvement and clinical stability at Week 52'

Financial news for RARE dated on 2018-09-26: Stocks Which Set New 52-Week High Yesterday, September 25th

Financial news for RARE dated on 2018-09-26: The Daily Biotech Pulse: Verastem's Chinese Duvelisib Licensing Deal, Aldeyra's Positive Dry Eye Disease Drug Trial

Financial news for RARE dated on 2018-09-25: Stocks Which Set New 52-Week High Yesterday, September 24th

Financial news for RARE dated on 2018-09-25: The Daily Biotech Pulse: Syndax Lung Cancer Trial Disappoints, Gemphire To Trim Workforce, Opiant's Offering

Financial news for RARE dated on 2018-09-11: Bank of America Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to \$94

Financial news for RARE dated on 2018-09-10: Morgan Stanley Assumes Ultragenyx Pharmaceutical at Equal-Weight, Announces Price Target \$92

Financial news for RARE dated on 2018-09-07: Stocks That Made New 52-Week Highs Yesterday, September 6th

Financial news for RARE dated on 2018-09-06: Stocks Which Set New 52-Week High Yesterday, September 5th

Financial news for RARE dated on 2018-09-06: The Daily Biotech Pulse: Novartis Divestment, Eyepoint's Drug Gets Coverage, Spectrum's Robust Data

Financial news for RARE dated on 2018-08-30: 10 Biggest Price Target Changes For Thursday

Financial news for RARE dated on 2018-08-30: Wedbush Maintains Outperform on Ultragenyx Pharmaceutical, Raises Price Target to \$90

Financial news for RARE dated on 2018-08-29: 34 Stocks Moving In Wednesday's Mid-Day Session

Financial news for RARE dated on 2018-08-29: Ultragenyx shares are up 8.3% after the FDA accepted the company's proposal to submit a New Drug Application (NDA) for UX007 for the treatment of long-chain fatty acid oxidation disorders.

Financial news for RARE dated on 2018-08-29: Ultragenyx Announces FDA Accepts Proposal to Submit an NDA for UX007

Financial news for RARE dated on 2018-08-28: The Daily Biotech Pulse: Regulatory Roadblock For Akcea-Ionis, Affimed's Alliance, FDA Nod For Tetrphase's Antibiotic

Financial news for RARE dated on 2018-08-27: Ultragenyx Announces European Commission Has Approved Its Mepsevii Marketing Authorization Application

Financial news for RARE dated on 2018-08-22: Ultragenyx Pharma 8-K Shows Co. Sent Blackout Trading Restriction Notice To Its Directors, Execs Informing They Will Be Prohibited From Engaging In Certain Transactions Through Aug. 24, 2018 To Sept. 30, 2018

Financial news for RARE dated on 2018-08-06: Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to \$92

Financial news for RARE dated on 2018-08-06: Wedbush Maintains Outperform on Ultragenyx Pharmaceutical, Raises Price Target to \$80

Financial news for RARE dated on 2018-08-03: Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to \$90

Financial news for RARE dated on 2018-08-02: Ultragenyx Pharmaceutical Q2 EPS \$(1.06) Beats \$(2.09) Estimate, Sales \$12.794M Beat \$5.42M Estimate

Financial news for RARE dated on 2018-07-26: Ultragenyx Reports First Patient Dosed In Phase 1/2 Study Of DTX401 For Treatment Of GSDIa; FDA Granted Fast Track Designation for Gene Therapy Program

Financial news for RARE dated on 2018-07-19: Leerink Swann Maintains Outperform on Ultragenyx Pharmaceutical, Raises Price Target to \$95

Financial news for RARE dated on 2018-06-29: EU Recommends Approval Of Novartis Kymriah, Recommends Approval Of Ultragenyx Drug For Treatment Of Sly Syndrome, Recommends Approval Of Yescarta

Financial news for RARE dated on 2018-06-21: Benzinga's Top Upgrades, Downgrades For June 21, 2018

Financial news for RARE dated on 2018-06-21: Benzinga's Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street

Financial news for RARE dated on 2018-06-21: Credit Suisse Downgrades Ultragenyx Pharmaceutical to Neutral, Raises Price Target to \$80

Financial news for RARE dated on 2018-06-15: Benzinga's Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid Addiction Drug

Financial news for RARE dated on 2018-06-08: Benzinga's Daily Biotech Pulse: EDAP Device Gets FDA Nod, Amplphi Presents Positive Data, Agile To Cut Jobs

Financial news for RARE dated on 2018-06-07: Benzinga's Daily Biotech Pulse: Johnson & Johnson to Dispose Sterilization Products Business, Mixed Results From Protesostasis' Cystic Fibrosis Study

Financial news for RARE dated on 2018-06-01: Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO

Financial news for RARE dated on 2018-05-31: Benzinga's Daily Biotech Pulse: Clinical Hold For Crispr, Gilead Study Meets Endpoint, Akers Gets Grace Time

Financial news for RARE dated on 2018-05-24: Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings

Financial news for RARE dated on 2018-05-23: Ultragenyx, Kyowa Kirin Publish Phase 2 Results Showing Crysvita Improved Outcomes In Children With X-Linked Hypophosphatemia In NEJM

Financial news for RARE dated on 2018-05-17: Ultragenyx Pharma, Kyowa Kirin Report Topline Phase 3 Study Results For Crysvita For Treatment To Oral Phosphate, Active Vitamin D In Children With X-Linked Hypophosphatemia: Met Primary Endpoint

Financial news for RARE dated on 2018-05-11: Benzinga's Top Upgrades, Downgrades For May 11, 2018

Financial news for RARE dated on 2018-05-11: Barclays Upgrades Ultragenyx Pharmaceutical to Overweight

Financial news for RARE dated on 2018-05-10: Benzinga's Top Upgrades, Downgrades For May 10, 2018

Financial news for RARE dated on 2018-05-10: Goldman Sachs Initiates Coverage On Ultragenyx Pharmaceutical with Neutral Rating, Announces \$63 Price Target

Financial news for RARE dated on 2018-05-07: Ultragenyx Pharmaceutical Q1 Adj. EPS \$(2.03), Sales \$10.677M Miss \$52.86M Estimate

Financial news for RARE dated on 2018-05-06: The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Financial news for RARE dated on 2018-04-23: Ultragenyx Reports Filing, FDA Clearance Of INDA For DTX401 For Glycogen Storage Disease Type Ia

Financial news for RARE dated on 2018-04-18: Benzinga's Top Upgrades, Downgrades For April 18, 2018

Financial news for RARE dated on 2018-04-18: SunTrust Robinson Humphrey Upgrades Ultragenyx Pharmaceutical to Buy

Financial news for RARE dated on 2018-04-17: Ultragenyx, Kyowa Kirin Report FDA Approval Of Crysvita (Burosumab) for Treatment Of Children, Adults With X-Linked Hypophosphatemia

Financial news for RARE dated on 2018-04-17: UPDATE: BofA/Merrill On Ultragenyx Says Following FDA Approval Of Burosumab, Firm Removes 'risk assumption for US sales in our model and now est. risk-adj. 2018 sales of \$74mn'; Firm Had Previously Expected Sales Of \$59M

Financial news for RARE dated on 2018-04-17: Ultragenyx Shares Spike ~\$0.20 Higher Over \$55 Level Following Mid-Day Price Target Increase From \$61 To \$72 By BofA/Merrill, Buy Rating Reiterated

Financial news for RARE dated on 2018-04-17: PR Confirms Ultragenyx and Kyowa Kirin Announce FDA Approval of Crysvita, Ultragenyx to Host Conference Call Today at 4:30 pm Eastern Time

Financial news for RARE dated on 2018-04-17: FDA Says It Granted Approval Of Crysvita To Ultragenyx Pharmaceutical

Financial news for RARE dated on 2018-04-17: REMINDER: FDA PDUFA Dates Today Include: Ultragenyx BLA for Burosumab and Rigel Pharma for Fostamatinib

Financial news for RARE dated on 2018-04-16: The Week Ahead: Netflix Earnings, Big Bank Results, FDA Actions Abound

Financial news for RARE dated on 2018-04-13: The Week Ahead In Biotech: PDUFA Dates, IPOs And More

Financial news for RARE dated on 2018-04-03: Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates

Financial news for RARE dated on 2018-03-07: Ultragenyx Provides Topline Results And DMC Review From First Cohort Of Phase 1/2 Clinical Study Of DTX301, Says 2 of 3 Patients Didn't Show A Clinically Meaningful Change In Rate Of Ureagenesis Over 12 And 20 Weeks Respectively

Financial news for RARE dated on 2018-02-23: Kyowa Kirin and Ultragenyx Announce Crysvita Receives Conditional Marketing Authorization in Europe

Financial news for RARE dated on 2018-02-21: Morgan Stanley Maintains Equal-Weight on Ultragenyx Pharmaceutical, Raises price target to \$60.00

Financial news for RARE dated on 2018-02-21: JP Morgan Maintains Overweight on Ultragenyx Pharmaceutical, Lowers price target to \$66.00

Financial news for RARE dated on 2018-02-20: Ultragenyx Reports Q4 EPS \$(1.89) vs \$(1.99) Est., Sales \$2.414M vs \$5K In Same Qtr. Last Year

Financial news for RARE dated on 2018-01-24: Late Tuesday Ultragenyx Announced Common Stock Offering Priced At \$57/Share

Financial news for RARE dated on 2018-01-23: Ultragenyx Pharma Shares Down 7.32% After Monday Filing For \$175M Common Stock Offering

Financial news for RARE dated on 2018-01-23: 38 Biggest Movers From Yesterday

Financial news for RARE dated on 2018-01-22: Ultragenyx Announces \$175M Offering Common Stock

Financial news for RARE dated on 2018-01-22: 32 Stocks Moving In Monday's Mid-Day Session

Financial news for RARE dated on 2018-01-22: Ultragenyx Shares Up 11% Following Evercore ISI Upgrade From In-Line To Outperform

Financial news for RARE dated on 2018-01-17: Credit Suisse Initiates Coverage On Ultragenyx Pharmaceutical with Outperform Rating, Announces \$67.00 Price Target

Financial news for RARE dated on 2018-01-10: JP Morgan Healthcare Conference Continues Today, Presenters Include: Quidel, NovoCure, Acorda, PerkinElmer, Glaukos, IDEXX, MiMedx, Community Health, Global Blood Therapeutics, and Ultragenyx

Financial news for RARE dated on 2018-01-07: Ultragenyx Announces Positive Interim Topline Results From First Cohort of Phase 1/2 Clinical Study of DTX301 Gene Therapy in OTC Deficiency

Financial news for RARE dated on 2017-12-18: Ultragenyx Sells Priority Review Voucher To Novartis for \$130M

Financial news for RARE dated on 2017-12-15: Ultragenyx Pharma, Kyowa Hakko Kirin Report Burosumab Received Positive CHMP Opinion For Treatment Of X-Linked Hypophosphatemia In Children

Financial news for RARE dated on 2017-12-04: The Week Ahead For December 4: The Biggest Catalysts, Conferences, And Investor Events

Financial news for RARE dated on 2017-12-04: Benzinga's Top Upgrades, Downgrades For December 4, 2017

Financial news for RARE dated on 2017-12-04: Jefferies Upgrades Ultragenyx Pharmaceutical to Buy

Financial news for RARE dated on 2017-12-04: Ultragenyx Pharmaceutical Says 84% Of Patients Who Received burosumab Achieved And Maintained Serum Phosphorus Levels Above The Lower Limit of Normal

Financial news for RARE dated on 2017-12-04: Ultragenyx and Kyowa Kirin Announce 'Positive' 48-Week Data from Adult Phase 3 Study of Burosumab (KRN23) in X-Linked Hypophosphatemia

Financial news for RARE dated on 2017-12-01: FDA Decisions In November: The Month In Review

Financial news for RARE dated on 2017-11-16: Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to \$80.00

Financial news for RARE dated on 2017-11-16: REMINDER: Ultragenyx Pharmaceuticals Has PDUFA Date For rhGUS Today

Financial news for RARE dated on 2017-11-16: Ultragenyx Reports Completion Of Patient Dosing In First Cohort Of Phase 1/2 Study Of DTX301 Gene Therapy In OTC Deficiency

Financial news for RARE dated on 2017-11-15: Ultragenyx Announces FDA Approval of MEPSEVII, Ultragenyx to Host Conference Call Today at 5:00pm ET

Financial news for RARE dated on 2017-11-15: Ultragenyx Seeks An FDA Win For Biologic Therapy Candidate

Financial news for RARE dated on 2017-11-13: The Week Ahead For November 13: Conferences, Earnings and IPO Events To Watch

Financial news for RARE dated on 2017-11-02: Ultragenyx Reports Q3 EPS \$(1.87) vs \$(1.86) Est.

Financial news for RARE dated on 2017-11-01: Ultragenyx, Kyowa Hakko Kirin Report FDA Is Not Currently Planning To Hold AdCom Panel Meeting For Burosumab BLA

Financial news for RARE dated on 2017-10-31: Attention Biotech Investors: Here Are November PDUFA Catalysts On The Horizon

Financial news for RARE dated on 2017-10-26: Ultragenyx, Dimension Therapeutics Report Expiration Of HSR Waiting Period For Deal

Financial news for RARE dated on 2017-10-10: Ultragenyx Reports FDA Acceptance, Priority Review Designation Of Burosumab BLA

Financial news for RARE dated on 2017-10-04: Wall Street's M&A Chatter From October 2: Kroger, ILG, Methode Electronics-Pacific Insight, Ultragenyx-Dimension

Financial news for RARE dated on 2017-10-03: Ultragenyx to Acquire Dimension Therapeutics For \$6/Share In A Deal Valued At ~\$151M

Financial news for RARE dated on 2017-10-03: Wall Street's M&A Chatter From October 2: CenturyLink-Level 3, Unilever-Mae Terras, Dimension-Ultragenyx

Financial news for RARE dated on 2017-10-02: Ultragenyx Offers Comment On News Co.'s Offer For Dimension Is 'Superior Proposal': 'We are pleased' With Determination, 'We look forward to completing this transaction as quickly as possible...'

Financial news for RARE dated on 2017-10-02: Dimension Therapeutics Reports Board Has Determined Ultragenyx's Offer To Buy Co. At \$6/Share Constitutes A 'Superior Proposal'

Financial news for RARE dated on 2017-09-19: Wall Street's M&A Chatter From September 18: Walgreens-Rite Aid, Northrup Grumman-Orbital ATK, Itron-Silver Spring Networks

Financial news for RARE dated on 2017-09-19: Dimension Therapeutics Reports Board Has Determined Ultragenyx's Offer 'Could Reasonably Be Expected to Lead to a Superior Proposal'

Financial news for RARE dated on 2017-09-18: UPDATE: Dimension Says It Will Review The Ultragenyx Proposal And Will Not Comment Further Until That Review Is Complete

Financial news for RARE dated on 2017-09-18: Dimension Therapeutics Press Release Confirms Receipt Of Unsolicited Offer Of \$5.50/Share Cash From Ultragenyx To Acquire The Co.

Financial news for RARE dated on 2017-09-18: Dimension Therapeutics Shares Were Halted Following Announcement Of Proposal To Purchase Co. At \$5.50/Share In Cash By Ultragenyx Pharma

Financial news for RARE dated on 2017-09-14: The Market In 5 Minutes

Financial news for RARE dated on 2017-09-14: Benzinga's Top Upgrades, Downgrades For September 14, 2017

Financial news for RARE dated on 2017-09-14: Wedbush Upgrades Ultragenyx Pharmaceutical to Outperform

Financial news for RARE dated on 2017-09-11: UPDATE: Ultragenyx Says 'All other events were assessed as mild or moderate in severity except for a Grade 3 food allergy that was considered unrelated to burosumab treatment'

Financial news for RARE dated on 2017-09-11: UPDATE: Ultragenyx Says 'All patients experienced one or more adverse events. There was one serious adverse event of a tooth abscess that was considered unrelated to burosumab treatment'

Financial news for RARE dated on 2017-09-11: UPDATE: Ultragenyx Says 'Burosumab increased mean serum phosphorus levels by 1.2 mg/dL into the low normal range after one week of treatment...'

Financial news for RARE dated on 2017-09-11: Ultragenyx, Kyowa Hakko Kirin Report Announcement Of Added Burosumab Data In XLH, TIO At American Society for Bone and Mineral Research Meeting

Financial news for RARE dated on 2017-09-07: Barclays Initiates Coverage On Ultragenyx Pharmaceutical with Equal-Weight Rating, Announces \$60.00 Price Target

Financial news for RARE dated on 2017-08-24: Ultragenyx Pharmaceutical and Kyowa Hakko Kirin Announce Submission Of Biologics License Application With FDA For burosumab

Financial news for RARE dated on 2017-08-23: 15 Biggest Mid-Day Losers For Wednesday

Financial news for RARE dated on 2017-08-23: Ultragenyx Discontinues Phase 3 GNE Myopathy Study

Financial news for RARE dated on 2017-08-23: 5 Biggest Price Target Changes For Wednesday

Financial news for RARE dated on 2017-08-23: Benzinga's Top Upgrades, Downgrades For August 23, 2017

Financial news for RARE dated on 2017-08-23: 18 Stocks Moving In Wednesday's Pre-

Market Session

Financial news for RARE dated on 2017-08-23: SunTrust Robinson Humphrey Downgrades Ultragenyx Pharmaceutical to Hold

Financial news for RARE dated on 2017-08-22: Ultragenyx Shares Resume Trade, Down ~11%

Financial news for RARE dated on 2017-08-22: Ultragenyx Shares Were Halted To Announce Results Of Phase 3 Study, Will Resume Trade At 4:25 p.m. EDT

Financial news for RARE dated on 2017-08-22: Ultragenyx Reports Results From Phase 3 Study Of Ace-ER In GNE Myopathy: Did Not Meet Primary, Key Secondary Endpoints

Financial news for RARE dated on 2017-08-17: Evercore ISI Group Initiates Coverage On Ultragenyx Pharmaceutical with In-Line Rating, Announces \$63.00 Price Target

Financial news for RARE dated on 2017-07-27: Bernstein Initiates Coverage On Ultragenyx Pharmaceutical with Market Perform Rating, Announces \$72.00 Price Target

Financial news for RARE dated on 2017-06-23: Ultragenyx Offers Update On KRN23: BLA Filing Planned With Current Clinical Data Package In 2H'17

Financial news for RARE dated on 2017-06-22: Companies Holding Shareholder Meetings Today Include: Apogee, Cherokee, Citrix Systems, Kroger, Mylan, Pier 1, TripAdvisor, VBI Vaccines, Universal Display, Ultragenyx Pharma, and ZAGG

Financial news for RARE dated on 2017-06-18: Ultragenyx Pharmaceutical Receives FDA Orphan Designation for Tazemetostat

Financial news for RARE dated on 2017-06-07: 22 Stocks Moving In Wednesday's Pre-Market Session

Financial news for RARE dated on 2017-05-23: Ultragenyx Reports Recombinant Human Beta-Glucuronidase BLA, MAA Filed, Accepted for Review, Announces FDA Has Granted Priority Review Status

Financial news for RARE dated on 2017-05-16: Bank Of America Health Care Conference Begins Today; Presenters Include Luminex, Acadia Healthcare, Express Scripts, Puma Biotech, Ultragenyx Pharma, Alexion, Medicines Co., Juno, TherapeuticsMD, & Seattle Genetics

Financial news for RARE dated on 2017-05-04: Ultragenyx Reports Q1 EPS \$(1.63) vs \$(1.71) Est.

Financial news for RARE dated on 2017-04-27: Ultragenyx Reports Initiation of Global Phase 3 Study of UX007 in Glut1 DS Patients

Financial news for RARE dated on 2017-04-19: 15 Biggest Mid-Day Gainers For Wednesday

Financial news for RARE dated on 2017-04-19: Analyst Sees Ultragenyx Shares Range Bound Despite Positive Data

Financial news for RARE dated on 2017-04-19: 7 Biggest Price Target Changes For Wednesday

Financial news for RARE dated on 2017-04-19: The Next Steps For Ultragenyx' Burosumab Following Positive Phase 3 Data

Financial news for RARE dated on 2017-04-19: Benzinga's Top Upgrades, Downgrades For April 19, 2017

Financial news for RARE dated on 2017-04-19: 22 Stocks Moving In Wednesday's Pre-Market Session

Financial news for RARE dated on 2017-04-19: Wedbush Downgrades Ultragenyx Pharmaceutical to Neutral, Lowers Price Target to \$75.00

Financial news for RARE dated on 2017-04-19: H.C. Wainwright Downgrades Ultragenyx Pharmaceutical to Neutral, Lowers Price Target to \$72.00

Financial news for RARE dated on 2017-04-19: Ultragenyx +13% Premarket; Co Announced Tuesday Phase 3 Study of KRN23 Met Primary Endpoint

Financial news for RARE dated on 2017-04-18: Ultragenyx, Kyowa Hakko Kirin, Announce Phase 3 Study of KRN23 Met Primary Endpoint

Financial news for RARE dated on 2017-04-06: 12 Biggest Mid-Day Losers For Thursday

Financial news for RARE dated on 2017-04-06: 7 Biggest Price Target Changes For Thursday

Financial news for RARE dated on 2017-04-06: Benzinga's Top Upgrades, Downgrades For April 6, 2017

Financial news for RARE dated on 2017-04-06: Ultragenyx, Kyowa Kirin Report Data from Pediatric Phase 2 Studies of KRN23 in X-Linked Hypophosphatemia

Financial news for RARE dated on 2017-04-06: Jefferies Downgrades Ultragenyx Pharmaceutical To Hold, Lowers Price Target To \$66

Financial news for RARE dated on 2017-03-23: 15 Biggest Mid-Day Losers For Thursday

Financial news for RARE dated on 2017-03-23: 5 Biggest Price Target Changes For Thursday

Financial news for RARE dated on 2017-03-23: Wedbush Lowers Ultragenyx Pharmaceutical Price Target On New Outlook

Financial news for RARE dated on 2017-03-23: Benzinga's Top Upgrades, Downgrades For March 23, 2017

Financial news for RARE dated on 2017-03-23: The Market In 5 Minutes

Financial news for RARE dated on 2017-03-23: 18 Stocks Moving In Thursday's Pre-Market Session

Financial news for RARE dated on 2017-03-23: PiperJaffray Downgrades Ultragenyx Pharmaceutical To Neutral

Financial news for RARE dated on 2017-03-23: Wedbush Reiterates Outperform On Ultragenyx Pharmaceutical, Lowers Price Target To \$80

Financial news for RARE dated on 2017-03-22: Ultragenyx Announces Topline Data From Phase 2 UX007 Study, Did Not Meet Primary Endpoint

Financial news for RARE dated on 2017-02-16: Ultragenyx Reports Q4 EPS \$(1.75) vs. \$(1.72) Est.

Financial news for RARE dated on 2017-01-05: Ultragenyx, Kyowa Kirin International Announce Marketing Authorization Application for KRN23 Filed and Accepted for Review by EMA

Financial news for RARE dated on 2016-11-30: Ultragenyx Spikes Higher on Volume

Financial news for RARE dated on 2016-11-30: Ultragenyx Announces Positive Data from Phase 2 Study of UX007 in Long-Chain Fatty Acid Oxidation Disorder Patients, Reductions observed in frequency and total duration of major medical events

Financial news for RARE dated on 2016-11-14: 12 Biggest Mid-Day Losers For Monday

Financial news for RARE dated on 2016-11-14: Risk Confirmed: Ultragenyx Shares Downgraded To Sell By Citi

Financial news for RARE dated on 2016-11-14: Benzinga's Top Downgrades

Financial news for RARE dated on 2016-11-14: Citigroup Downgrades Ultragenyx Pharmaceutical Inc. - Common Stock to Sell, Lowers to \$64.00

Financial news for RARE dated on 2016-11-11: Ultragenyx Announces Withdrawal of Marketing Authorization Application for Aceneuramic Acid Prolonged Release (Ace-ER) in the European Union

Financial news for RARE dated on 2016-11-07: Ultragenyx Reports Q3 EPS \$(1.64) vs \$(1.53) Est., \$(1.03) in Same Qtr. Last Year, Sales \$111K vs \$1.16M Est.

Financial news for RARE dated on 2016-10-26: Ultragenyx Reports First Patient Enrolled in Global Phase 3 Study of KRN23 in Pediatric Patients with X-Linked Hypophosphatemia

Financial news for RARE dated on 2016-09-20: Jefferies Highlights Clinically Meaningful Data From Ultragenyx On KRN23

Financial news for RARE dated on 2016-09-19: UPDATE: Ultragenyx Says Will Still Conduct KRN23 Phase 3 Trial Even If Granted Accelerated Approval

Financial news for RARE dated on 2016-09-19: Ultragenyx Reports Positive Phase 2 Study Data

Financial news for RARE dated on 2016-09-19: On Ultragenyx Conference Call Exec Says Will Meet With FDA To Discuss Accelerated Approval Of KRN23

Financial news for RARE dated on 2016-09-19: Ultragenyx Announces Interim Data from Pediatric, Adult Phase 2 Studies of KRN23 in X-Linked Hypophosphatemia: Showed Substantial Reduction in Bone Disease, Improvement in Growth

Financial news for RARE dated on 2016-09-19: UPDATE: Ultragenyx Reported Interim Data at 24 Weeks from First Eight Patients Showed KRN23 Improved Serum Phosphorus Levels, Bone Metabolism Measures

Financial news for RARE dated on 2016-09-19: Ultragenyx Shares Indicated Higher in Premarket as Co. Announced Sunday Morning Positive Interim Data from Phase 2 Study of KRN23 for Treatment of TIO

Financial news for RARE dated on 2016-09-16: Ultragenyx Shares Continue Higher Fri., Up 3%; Shares Up 16% Over Sept.; Seeing Unusual Buying at Oct. 21 \$80 Call Contract; BZ NOTE: Activity Implies Move Up to \$85.70 in Stock Price Over Next Month

Financial news for RARE dated on 2016-09-13: Stocks With Three-Day Increasing Volume

Financial news for RARE dated on 2016-08-08: Ultragenyx Reports Q2 Loss -\$1.46 vs Est Loss/Share -\$1.44, Rev \$17K

Financial news for RARE dated on 2016-07-15: A Peek Into The Markets: U.S. Stock Futures Edge Higher Ahead Of Bank Earnings

Financial news for RARE dated on 2016-07-15: Ultragenyx's Final Stage Study Of Recombinant Human Beta-Glucuronidase Meets Primary Endpoint

Financial news for RARE dated on 2016-07-14: Ultragenyx Shares Trading Up Nearly 3% Following Favorable Phase 3 Results of rhGUS, UX003

Financial news for RARE dated on 2016-07-14: UPDATE: Ultragenyx Says Plans to Meet with FDA, EMA This Year to Discuss Plans to Submit Regulatory Filings in 1H'17

Financial news for RARE dated on 2016-07-14: Ultragenyx Reports Topline Data from Phase 3 Trial of rhGUS, UX003: Met Primary Endpoint of Reduction in Urinary GAG Excretion

Financial news for RARE dated on 2016-07-07: Benzinga's Top Initiations

Financial news for RARE dated on 2016-07-07: The Market In 5 Minutes: Improved Jobless Claims, A Big Food Acquisition And Pepsi's Latest Earnings

Financial news for RARE dated on 2016-07-07: Piper Jaffray Initiates Coverage on Ultragenyx Pharmaceutical at Overweight, Announces \$70.00 PT

Financial news for RARE dated on 2016-06-28: Wedbush Recommending Clients Buy RARE, Says '...BTD for KRN23 supports our view that it is differentiated from standard of care with the ability to improve outcomes', Maintains Outperform

Financial news for RARE dated on 2016-06-28: Benzinga's Top Initiations

Financial news for RARE dated on 2016-06-28: Ultragenyx Receives Breakthrough Therapy Designation for KRN23

Financial news for RARE dated on 2016-06-28: Bank of America Initiates Coverage on Ultragenyx Pharmaceutical at Buy

Financial news for RARE dated on 2016-06-17: Chief Medical Officer Resignation Will Not Affect Ultragenyx's Catalyst-Rich Timeline

Financial news for RARE dated on 2016-06-16: Ultragenyx Pharmaceutical Chief Medical Officer Sunil Agarwal to Resign Effective August 18, 2016

Financial news for RARE dated on 2016-06-13: Leerink Raises Ultragenyx Pharma's Price Target On Confidence In MPS 7 Treatment

Financial news for RARE dated on 2016-06-07: UPDATE: Takeda Pharma Will Make Up to \$65M Investment in Ultragenyx, via Two Tranches

Financial news for RARE dated on 2016-06-07: Ultragenyx Pharma, Takeda Pharma Report Collab for Development, Commercialization of Therapies for Rare Genetic Diseases

Financial news for RARE dated on 2016-05-09: Ultragenyx Reports Q1 EPS \$(1.35) vs \$(1.29) Est.

Financial news for RARE dated on 2016-04-21: Ultragenyx Pharmaceutical Spikes 4% Following Release Of Positive Phase 2 Data

Financial news for RARE dated on 2016-04-21: Ultragenyx Reports Postitive Interim Data For Phase 2 KRN23 Study, Reported No SAE's And Treatment Can Restore Serum Phosphorus Levels And May Have Meaningful Effect On Bone Health In Patients

Financial news for RARE dated on 2016-04-12: Chardan Analyst: Amicus Therapeutics Could Be Bought For \$22.50/Share

Financial news for RARE dated on 2016-03-29: More Mid-Cap Biotech M&A May Be Coming

Financial news for RARE dated on 2016-03-23: Ultragenyx Reports Deal with Saint Louis University's Center for World Health, Medicine Research Collab to Advance Muscular Dystrophy Treatment

Financial news for RARE dated on 2016-03-08: Baird Buying Ultragenyx And BioMarin

Financial news for RARE dated on 2016-03-08: Monday After Hours Baird Initiated RARE At Outperform, Firm Sees A Plethora Of Meaningful Value-Creating Events Manifesting In Coming Year W/ Potential To Drive Upside

Financial news for RARE dated on 2016-03-07: Baird Initiates Coverage on Ultragenyx Pharmaceutical at Outperform, Announces \$85.00 PT

Financial news for RARE dated on 2016-02-19: Benzinga's Top Initiations

Financial news for RARE dated on 2016-02-19: Leerink Swann Initiates Coverage on Ultragenyx Pharmaceutical at Outperform, Announces \$80.00 PT

Financial news for RARE dated on 2016-02-09: Ultragenyx Has Multiple Catalysts This Year, Says H.C. Wainwright

Financial news for RARE dated on 2016-02-09: Benzinga's Top Initiations

Financial news for RARE dated on 2016-02-09: Credit Suisse Sees RARE Pullback As Buying Opportunity, Says Kyowa Hakko Kirin Estimates For Addressable XLH Patients Is Flawed

Financial news for RARE dated on 2016-02-09: Credit Suisse Maintains Outperform on Ultragenyx Pharmaceutical, Lowers PT to \$106.00

Financial news for RARE dated on 2016-02-09: H.C. Wainwright Initiates RARE With Buy, Expects Key Milestone Achievements Tied To KRN23, rhGUS, UX007, And AceER To Drive Share Price,

Financial news for RARE dated on 2016-02-09: H.C. Wainwright Initiates Coverage on Ultragenyx Pharmaceutical at Buy, Announces \$104.00 PT

Financial news for RARE dated on 2016-01-21: Credit Suisse Initiates On Smid-Cap Biotechs, Reveals Favorite Stock Picks

Financial news for RARE dated on 2016-01-20: Credit Suisse Initiates Coverage on Ultragenyx Pharmaceutical at Outperform, Announces \$135.00 PT

Financial news for RARE dated on 2016-01-12: Citigroup Upgrades Ultragenyx Pharmaceutical to Neutral

Financial news for RARE dated on 2016-01-06: Jefferies' Best Biotech Ideas For 2016 (And Beyond)

Financial news for RARE dated on 2015-12-21: Canaccord Genuity Initiates Coverage on Ultragenyx Pharmaceutical at Buy, Announces \$126.00 PT

Financial news for RARE dated on 2015-12-02: Ultragenyx Reports Positive Interim 40-Week Data From Pediatric Phase 2 Study of KRN23 in X-Linked Hypophosphatemia

Financial news for RARE dated on 2015-11-09: Ultragenyx Reports Q3 EPS \$(1.03) vs. Est. \$(0.87)

Financial news for RARE dated on 2015-11-06: Ultragenyx Announces Update to UX007 Development Program in Glucose Transporter Type-1 Deficiency Syndrome

Financial news for RARE dated on 2015-10-29: US Stock Futures Drop Ahead Of Earnings, Economic Data

Financial news for RARE dated on 2015-10-29: Ultragenyx Pharmaceutical, Arcturus Therapeutics Announce Research Collaboration, License Agreement

Financial news for RARE dated on 2015-10-13: Ultragenyx Announces Positive Interim Data From Phase 2 Study of UX007 in Long-Chain Fatty Acid Oxidation Disorder Patients

Financial news for RARE dated on 2015-10-02: Ultragenyx Announces Aceneuramic Acid Prolonged Release Marketing Authorization Application Filed and Accepted for Review by European Medicines Agency

Financial news for RARE dated on 2015-09-22: Monday's After-Hours Movers Led By Vascular Biogenics, Ultragenyx And Red Hat

Financial news for RARE dated on 2015-09-03: Benzinga's Top Initiations

Financial news for RARE dated on 2015-09-01: Ultragenyx Announces Presentation of Data From Long-Chain Fatty Acid Oxidation Disorder Patients With Cardiomyopathy Treated With Triheptanoin

Financial news for RARE dated on 2015-08-13: Ultragenyx Pharmaceutical Reports Q2 Loss \$0.83 Vs Est Loss \$0.63

Financial news for RARE dated on 2015-08-13: This Week's First IPO: Global Blood Therapeutics Developing Drugs For Diseases Affecting Few

Financial news for RARE dated on 2015-08-13: 8-K from Ultragenyx Pharma Shows Amendment to Collaboration, License Deal with Nobelpharma for Supplying of Product

Financial news for RARE dated on 2015-08-05: Ultragenyx Announces Initiation of Phase 2 Study of Recombinant Human Beta-Glucuronidase in Patients Under Five Years Old With Mucopolysaccharidosis 7, FDA Fast Tracks rhGUS Program In MPS 7

Financial news for RARE dated on 2015-07-27: Ultragenyx Downgraded At Morgan Stanley, Valuation 'Stretched' And Pipeline Faces Execution Risk

Financial news for RARE dated on 2015-07-27: Morgan Stanley Downgrades Ultragenyx Pharmaceutical to Equal-weight, Raises PT to \$126.00

Financial news for RARE dated on 2015-07-16: Benzinga's Top #PreMarket Losers

Financial news for RARE dated on 2015-07-16: Ultragenyx Prices 2.2M Share Offering @\$120/Share

Financial news for RARE dated on 2015-07-14: Ultragenyx Reports Offering Of \$250M Shares Of Stock

Financial news for RARE dated on 2015-07-09: Stocks Hitting 52-Week Highs

Financial news for RARE dated on 2015-07-09: Benzinga's Top Initiations

Financial news for RARE dated on 2015-07-09: Ultragenyx Releases Positive Interim 40-Week Bone Treatment Data From Ongoing Pediatric Phase 2 Study of KRN23 in X-Linked Hypophosphatemia

Financial news for RARE dated on 2015-07-09: JMP Starts Ultragenyx At Outperform, Pipeline Maturity Expected To Continue

Financial news for RARE dated on 2015-07-09: JMP Securities Initiates Coverage on Ultragenyx Pharmaceutical at Outperform, Announces \$119.00 PT

Financial news for RARE dated on 2015-06-25: Ultragenyx Names Daniel Welch Chair

Financial news for RARE dated on 2015-06-22: Ultragenyx Names Jayson Dallas Chief Commercial Officer

Financial news for RARE dated on 2015-06-08: Ultragenyx Finalizes Enrollment in Phase 3 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis Type 7

Financial news for RARE dated on 2015-06-02: Ultragenyx Reports Positive 16-Week Interim Data from Pediatric Phase 2 Study of KRN23: No Serious Adverse Events Reported, Sees Potential Conditional Approval Pathway in Europe

Financial news for RARE dated on 2015-05-28: Ultragenyx Reports First Patient Enrolled in Global Phase 3 Study of Aceneuramic Acid (Sialic Acid) Extended Release in GNE Myopathy

Financial news for RARE dated on 2015-05-11: Ultragenyx Pharma Reports Q1 Loss \$0.63 Vs Est Loss \$0.54

Financial news for RARE dated on 2015-04-23: UltraGenyx Announces Wins Added Orphan Drug Designation for Triheptanoin

Financial news for RARE dated on 2015-04-22: Ultragenyx Offers Positive Data from Investigator-Sponsored Trial of Triheptanoin in Glucose Transporter Type-1 Deficiency

Financial news for RARE dated on 2015-04-22: Ultragenyx Reports Positive Data From Investigator-Sponsored Trial of Triheptanoin in Glucose Transporter Type-1 Deficiency Syndrome

Financial news for RARE dated on 2015-04-06: 16 Biotech Catalysts SunTrust Is Tracking

Financial news for RARE dated on 2015-03-31: Wedbush Initiates Coverage on Ultragenyx Pharmaceutical at Outperform, Announces \$74.00 PT

Financial news for RARE dated on 2015-03-31: UPDATE: MLV & Co Initiates Coverage On Ultragenyx Pharmaceutical On Positive Outlook

Financial news for RARE dated on 2015-03-30: MLV & Co Initiates Coverage on Ultragenyx Pharmaceutical at Buy, Announces \$79.00 PT

Financial news for RARE dated on 2015-03-25: Ultragenyx Reports Q4 EPS -\$0.52 Vs Est -\$0.53

Financial news for RARE dated on 2015-03-25: CRT Capital Initiates Coverage On Ultragenyx Pharmaceutical

Financial news for RARE dated on 2015-03-24: CRT Capital Initiates Coverage on Ultragenyx Pharmaceutical at Buy, Announces \$90.00 PT

Financial news for RARE dated on 2015-03-09: Ultragenyx Offers Presentation of Disease Burden Data in Adult Patients with X-Linked Hypophosphatemia

Financial news for RARE dated on 2015-02-10: Ultragenyx Announces Positive 36-Week Data From Phase 1/2 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis 7

Financial news for RARE dated on 2015-02-04: Ultragenyx Prices 3M Shares at \$54/Share

Financial news for RARE dated on 2015-02-03: Ultragenyx Announces \$125M Proposed Public Offering of Common Stock

Financial news for RARE dated on 2015-01-12: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2

Financial news for RARE dated on 2015-01-12: Ultragenyx Announces Intent to File For Conditional Approval In Europe For Sialic Acid Extended-Release Tablets

Financial news for RARE dated on 2015-01-07: Wednesday's After-Hours Movers

Financial news for RARE dated on 2015-01-07: Ultragenyx Reports License of IP Related to Treatment for Huntington's Disease Using Triheptanoin

Financial news for RARE dated on 2015-01-06: Ultragenyx Initiates New Development Program Studying KRN23 for the Treatment of Tumor-Induced Osteomalacia

Financial news for RARE dated on 2014-12-31: 19 Lesser-Known Biotech Stocks With Robust Drug Pipelines

Financial news for RARE dated on 2014-12-15: Mid-Morning Market Update: Markets Open Higher; BC Partners Group To Acquire PetSmart For \$83/Share

Financial news for RARE dated on 2014-12-15: Ultragenyx Announces Initiation Of Phase 3 Study Of Recombinant Human Beta-Glucuronidase

Financial news for RARE dated on 2014-11-10: Ultragenyx Reports Q3 EPS of \$(0.50) vs \$(0.46) Est

Financial news for RARE dated on 2014-10-30: Ultragenyx Wins EU Orphan Drug Designation for KRN23 for Treatment of X-Linked Hypophosphatemia

Financial news for RARE dated on 2014-10-27: Ultragenyx Announces Orphan Drug Designation for Triheptanoin for Treatment of Glucose Transporter Type-1 Deficiency Syndrome

Financial news for RARE dated on 2014-10-13: Ultragenyx Pharma Offers Interim Data from Phase 3 Extension Study of Sialic Acid ER at Int'l Congress of World Muscle Safety

Financial news for RARE dated on 2014-09-23: Benzinga's Top Initiations

Financial news for RARE dated on 2014-09-23: Jefferies Initiates Ultragenyx Pharmaceutical At Buy

Financial news for RARE dated on 2014-09-23: Jefferies Initiates Coverage on Ultragenyx at Buy, Announces \$74.00 PT

Financial news for RARE dated on 2014-09-22: 3 Partnerships Pushing The Pharmaceutical Sector Forward

Financial news for RARE dated on 2014-09-15: Ultragenyx Announces Positive Results From A Long-Term Phase 1/2 Study Of KRN23 In Adult Patients With X-Linked Hypophosphatemia

Financial news for RARE dated on 2014-09-03: Ultragenyx Offers Positive Interim Data from Phase 1/2 Study of Recombinant Human Beta-Glucuronidase

Financial news for RARE dated on 2014-08-11: Ultragenyx Reports Q2 EPS of \$(0.45) vs \$(0.42) Est

Financial news for RARE dated on 2014-07-15: Baird Initiates Coverage on Ultragenyx at Outperform, Announces \$64.00 PT

Financial news for RARE dated on 2014-07-14: Ultragenyx Announces Closing of ~2.3M Share Offering at \$40, Net Proceeds ~\$60.2M

Financial news for RARE dated on 2014-07-09: US Stock Futures Flat; All Eyes On Fed Minutes

Financial news for RARE dated on 2014-07-09: Ultragenyx Announces Prices 2.017M Share Offering @\$40.00/Share

Financial news for RARE dated on 2014-07-07: Ultragenyx Announces Offering of ~2.017M Shares of Common Stock

Financial news for RARE dated on 2014-07-01: Ultragenyx Announces Initiation Of A Phase 2 Study of KRN23 For Pediatric X-Linked Hypophosphatemia In The US And EU

Financial news for RARE dated on 2014-06-24: Ultragenyx Announces Results From Phase 1/2 Study Involving KRN23 In X-Linked Hypophosphatemia In Adults

Financial news for RARE dated on 2014-05-12: Ultragenyx Reports Q1 EPS of \$(0.85) Which May Not Compare \$(0.37) Est

Financial news for RARE dated on 2014-03-28: Ultragenyx Exec at Future Leaders in the Biotech Industry Conference: Expecting FY14 Operating Loss Higher Than 2013, Sees Existing Cash Funding Operations Into 2016

Financial news for RARE dated on 2014-03-27: Ultragenyx Reports Prelim. Data from Phase 1/2 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis 7

Financial news for RARE dated on 2014-02-25: UPDATE: Morgan Stanley Initiates Coverage on Ultragenyx Pharmaceutical on Growing Orphan Drug Pipeline

Financial news for RARE dated on 2014-02-25: Benzinga's Top Initiations

Financial news for RARE dated on 2014-02-25: Canaccord Genuity Initiates Coverage on Ultragenyx at Buy, Announces \$85.00 PT

Financial news for RARE dated on 2014-02-25: JP Morgan Initiates Coverage on Ultragenyx at Overweight, Announces \$66.00 PT

Financial news for RARE dated on 2014-02-25: Morgan Stanley Initiates Coverage on Ultragenyx at Overweight, Announces \$81.00 PT

Financial news for RARE dated on 2014-02-03: Six IPOs Hit Wall Street on Friday: CARA, TRVN, RARE, NWHM, SNOW, MBUU

Financial news for RARE dated on 2014-01-31: UPDATE: Ultragenyx Shares Now Over \$47.50 Level

Financial news for RARE dated on 2014-01-31: Shares of Ultragenyx Pharma Open for Trade Around \$45.30, Priced at \$21/Share

Financial news for RARE dated on 2014-01-30: Ultragenyx Prices 5.76M Share IPO at \$21/Share

Financial news for RARE dated on 2014-01-30: Ultragenyx Raises IPO Size to 4.8M Shares at \$19-\$20/Share